Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders, 57926-57928 [2020-20395]
Download as PDF
57926
Federal Register / Vol. 85, No. 180 / Wednesday, September 16, 2020 / Notices
billion extension notices). On August
11, 2020, the U.S. Trade Representative
announced a determination to extend
certain previously granted exclusions.
See 85 FR 48600 (August 11, 2020).
this notice, contact traderemedy@
cbp.dhs.gov.
SUPPLEMENTARY INFORMATION:
jbell on DSKJLSW7X2PROD with NOTICES
A. Background
For background on the proceedings in
this investigation, please see prior
notices including 82 FR 40213 (August
24, 2017), 83 FR 14906 (April 6, 2018),
83 FR 28710 (June 20, 2018), 83 FR
33608 (July 17, 2018), 83 FR 38760
(August 7, 2018), 83 FR 47974
(September 21, 2018), 83 FR 49153
(September 28, 2018), 83 FR 65198
(December 19, 2018), 84 FR 7966 (March
5, 2019), 84 FR 20459 (May 9, 2019), 84
FR 29576 (June 24, 2019), 84 FR 38717
(August 7, 2019), 84 FR 46212
(September 3, 2019), 84 FR 49591
(September 20, 2019), 84 FR 57803
(October 28, 2019), 84 FR 61674
(November 13, 2019), 84 FR 65882
(November 29, 2019), 84 FR 69012
(December 17, 2019), 85 FR 549 (January
6, 2020), 85 FR 6674 (February 5, 2020),
85 FR 9921 (February 20, 2020), 85 FR
15015 (March 16, 2020), 85 FR 17158
(March 26, 2020), 85 FR 23122 (April
24, 2020), 85 FR 27489 (May 8, 2020),
85 FR 32094 (May 28, 2020), 85 FR
38000 (June 24, 2020), 85 FR 42968 (July
15, 2020), and 85 FR 48600 (August 11,
2020).
Effective September 24, 2018, the U.S.
Trade Representative imposed
additional 10 percent ad valorem duties
on goods of China classified in 5,757
full and partial subheadings of the
Harmonized Tariff Schedule of the
United States (HTSUS), with an
approximate annual trade value of $200
billion. See 83 FR 47974, as modified by
83 FR 49153. In May 2019, the U.S.
Trade Representative increased the
additional duty to 25 percent. See 84 FR
20459. On June 24, 2019, the U.S. Trade
Representative established a process by
which stakeholders could request
exclusion of particular products
classified within an eight-digit HTSUS
subheading covered by the $200 billion
action from the additional duties. See 84
FR 29576 (June 24 notice). The U.S.
Trade Representative issued a notice
setting out the process for the product
exclusions and opened a public docket.
The exclusions the U.S. Trade
Representative granted under the $200
billion action expired on August 7,
2020. See, e.g., 84 FR 38717 (August 7,
2019).
On May 6 and June 3, 2020, the U.S.
Trade Representative invited the public
to comment on whether to extend by up
to 12 months, particular exclusions
granted under the $200 billion action.
See 85 FR 27011 (May 6, 2020) and 85
FR 34279 (June 3, 2020) (the $200
VerDate Sep<11>2014
18:20 Sep 15, 2020
Jkt 250001
B. Technical Amendment to Exclusion
The Annex to this notice contains one
technical amendment to U.S. note
20(iii)(252), to subchapter III of chapter
99 of the HTSUS, as set out in the
Annex of the notice published at 85 FR
48600 (August 11, 2020).
Annex
Effective with respect to goods entered for
consumption, or withdrawn from warehouse
for consumption, on or after 12:01 a.m.
eastern daylight time on August 7, 2020, and
before December 31, 2020, U.S. note
20(iii)(252) to subchapter III of chapter 99 of
the Harmonized Tariff Schedule of the
United States (HTSUS) is modified by
deleting ‘‘(described in statistical reporting
number 9403.20.0050)’’ and inserting
‘‘(described in statistical reporting number
9403.20.0050 or 9403.20.0078)’’ in lieu
thereof.
Joseph Barloon,
General Counsel, Office of the United States
Trade Representative.
[FR Doc. 2020–20384 Filed 9–15–20; 8:45 am]
BILLING CODE 3290–F0–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2020–0050]
Qualification of Drivers; Exemption
Applications; Epilepsy and Seizure
Disorders
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption; request for comments.
AGENCY:
FMCSA announces receipt of
applications from six individuals for an
exemption from the prohibition in the
Federal Motor Carrier Safety
Regulations (FMCSRs) against persons
with a clinical diagnosis of epilepsy or
any other condition that is likely to
cause a loss of consciousness or any loss
of ability to control a commercial motor
vehicle (CMV) to drive in interstate
commerce. If granted, the exemptions
would enable these individuals who
have had one or more seizures and are
taking anti-seizure medication to
operate CMVs in interstate commerce.
DATES: Comments must be received on
or before October 16, 2020.
ADDRESSES: You may submit comments
identified by the Federal Docket
SUMMARY:
PO 00000
Frm 00108
Fmt 4703
Sfmt 4703
Management System (FDMS) Docket No.
FMCSA–2020–0050 using any of the
following methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov/
docket?D=FMCSA-2020-0050. Follow
the online instructions for submitting
comments.
• Mail: Docket Operations; U.S.
Department of Transportation, 1200
New Jersey Avenue SE, West Building
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery: Docket Operations,
West Building Ground Floor, Room
W12–140, 1200 New Jersey Avenue SE,
Washington, DC, between 9 a.m. and 5
p.m., ET, Monday through Friday,
except Federal Holidays. To be sure
someone is there to help you, please call
(202) 366–9317 or (202) 366–9826
before visiting Docket Operations.
• Fax: (202) 493–2251.
To avoid duplication, please use only
one of these four methods. See the
‘‘Public Participation’’ portion of the
SUPPLEMENTARY INFORMATION section for
instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Operations, (202) 366–9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Submitting Comments
If you submit a comment, please
include the docket number for this
notice (Docket No. FMCSA–2020–0050),
indicate the specific section of this
document to which each comment
applies, and provide a reason for each
suggestion or recommendation. You
may submit your comments and
material online or by fax, mail, or hand
delivery, but please use only one of
these means. FMCSA recommends that
you include your name and a mailing
address, an email address, or a phone
number in the body of your document
so that FMCSA can contact you if there
are questions regarding your
submission.
To submit your comment online, go to
https://www.regulations.gov/
docket?D=FMCSA-2020-0050. Click on
the ‘‘Comment Now!’’ button and type
your comment into the text box on the
following screen. Choose whether you
E:\FR\FM\16SEN1.SGM
16SEN1
Federal Register / Vol. 85, No. 180 / Wednesday, September 16, 2020 / Notices
are submitting your comment as an
individual or on behalf of a third party
and then submit.
If you submit your comments by mail
or hand delivery, submit them in an
unbound format, no larger than 81⁄2 by
11 inches, suitable for copying and
electronic filing. If you submit
comments by mail and would like to
know that they reached the facility,
please enclose a stamped, self-addressed
postcard or envelope.
FMCSA will consider all comments
and material received during the
comment period.
B. Viewing Documents and Comments
To view comments, as well as any
documents mentioned in this notice as
being available in the docket, go to
https://www.regulations.gov/
docket?D=FMCSA-2020-0050 and
choose the document to review. If you
do not have access to the internet, you
may view the docket online by visiting
Docket Operations in Room W12–140
on the ground floor of the DOT West
Building, 1200 New Jersey Avenue SE,
Washington, DC 20590, between 9 a.m.
and 5 p.m., ET, Monday through Friday,
except Federal holidays. To be sure
someone is there to help you, please call
(202) 366–9317 or (202) 366–9826
before visiting Docket Operations.
jbell on DSKJLSW7X2PROD with NOTICES
C. Privacy Act
In accordance with 5 U.S.C. 553(c),
DOT solicits comments from the public
to better inform its rulemaking process.
DOT posts these comments, without
edit, including any personal information
the commenter provides, to
www.regulations.gov, as described in
the system of records notice (DOT/ALL–
14 FDMS), which can be reviewed at
www.transportation.gov/privacy.
II. Background
Under 49 U.S.C. 31136(e) and
31315(b), FMCSA may grant an
exemption from the FMCSRs for no
longer than a 5-year period if it finds
such exemption would likely achieve a
level of safety that is equivalent to, or
greater than, the level that would be
achieved absent such exemption. The
statute also allows the Agency to renew
exemptions at the end of the 5-year
period. FMCSA grants medical
exemptions from the FMCSRs for a 2year period to align with the maximum
duration of a driver’s medical
certification.
The six individuals listed in this
notice have requested an exemption
from the epilepsy and seizure disorders
prohibition in 49 CFR 391.41(b)(8).
Accordingly, the Agency will evaluate
the qualifications of each applicant to
VerDate Sep<11>2014
18:20 Sep 15, 2020
Jkt 250001
determine whether granting the
exemption will achieve the required
level of safety mandated by statute.
The physical qualification standard
for drivers regarding epilepsy found in
§ 391.41(b)(8) states that a person is
physically qualified to drive a CMV if
that person has no established medical
history or clinical diagnosis of epilepsy
or any other condition which is likely
to cause the loss of consciousness or any
loss of ability to control a CMV.
In addition to the regulations, FMCSA
has published advisory criteria 1 to
assist medical examiners (MEs) in
determining whether drivers with
certain medical conditions are qualified
to operate a CMV in interstate
commerce.
The criteria states that if an individual
has had a sudden episode of a nonepileptic seizure or loss of
consciousness of unknown cause that
did not require anti-seizure medication,
the decision whether that person’s
condition is likely to cause the loss of
consciousness or loss of ability to
control a CMV should be made on an
individual basis by the ME in
consultation with the treating physician.
Before certification is considered, it is
suggested that a 6-month waiting period
elapse from the time of the episode.
Following the waiting period, it is
suggested that the individual have a
complete neurological examination. If
the results of the examination are
negative and anti-seizure medication is
not required, then the driver may be
qualified.
In those individual cases where a
driver has had a seizure or an episode
of loss of consciousness that resulted
from a known medical condition (e.g.,
drug reaction, high temperature, acute
infectious disease, dehydration, or acute
metabolic disturbance), certification
should be deferred until the driver has
recovered fully from that condition, has
no existing residual complications, and
is not taking anti-seizure medication.
Drivers who have a history of
epilepsy/seizures, off anti-seizure
medication and seizure-free for 10 years,
may be qualified to operate a CMV in
interstate commerce. Interstate drivers
with a history of a single unprovoked
seizure may be qualified to drive a CMV
in interstate commerce if seizure-free
and off anti-seizure medication for a 5year period or more.
As a result of MEs misinterpreting
advisory criteria as regulation,
1 These criteria may be found in Appendix A to
Part 391—Medical Advisory Criteria, section H.
Epilepsy: § 391.41(b)(8), paragraphs 3, 4, and 5,
which is available on the internet at https://
www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/
CFR-2015-title49-vol5-part391-appA.pdf.
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
57927
numerous drivers have been prohibited
from operating a CMV in interstate
commerce based on the fact that they
have had one or more seizures and are
taking anti-seizure medication, rather
than an individual analysis of their
circumstances by a qualified ME based
on the physical qualification standards
and medical best practices.
On January 15, 2013, FMCSA
announced in a Notice of Final
Disposition titled, ‘‘Qualification of
Drivers; Exemption Applications;
Epilepsy and Seizure Disorders,’’ (78 FR
3069), its decision to grant requests from
22 individuals for exemptions from the
regulatory requirement that interstate
CMV drivers have ‘‘no established
medical history or clinical diagnosis of
epilepsy or any other condition which
is likely to cause loss of consciousness
or any loss of ability to control a CMV.’’
Since that time, the Agency has
published additional notices granting
requests from individuals for
exemptions from the regulatory
requirement regarding epilepsy found in
§ 391.41(b)(8).
To be considered for an exemption
from the epilepsy and seizure disorders
prohibition in § 391.41(b)(8), applicants
must meet the criteria in the 2007
recommendations of the Agency’s
Medical Expert Panel (78 FR 3069).
III. Qualifications of Applicants
Robert S. Kessler
Mr. Kessler is a 31year-old Class C
license holder in Kansas. He has a
history of epilepsy and has been seizure
free since 2004. He takes anti-seizure
medication with the dosage and
frequency remaining the same since
2016. His physician states that he is
supportive of Mr. Kessler receiving an
exemption.
Thomas J. Kline
Mr. Kline is a 56 year-old class C
license holder in Pennsylvania. He has
a history of seizures and has been
seizure free since 1990. He takes antiseizure medication with the dosage and
frequency remaining the same since
1990. His physician states that he is
supportive of Mr. Kline receiving an
exemption.
Jeffrey T. Lang
Mr. Lang is a 60 year-old CDL license
holder in Pennsylvania. He has a history
of a single witness seizure and has been
seizure free since 1996. He takes antiseizure medication with the dosage and
frequency remaining the same since
1997. His physician states that he is
supportive of Mr. Lang receiving an
exemption.
E:\FR\FM\16SEN1.SGM
16SEN1
57928
Federal Register / Vol. 85, No. 180 / Wednesday, September 16, 2020 / Notices
Ty Martin
Mr. Martin is a 45 year-old CDL
license holder in West Virginia. He has
a history of seizures and has been
seizure free since 2006. He takes antiseizure medication with the dosage and
frequency remaining the same since
2012. His physician states that she is
supportive of Mr. Martin receiving an
exemption.
Rick S. Morrison
Mr. Morrison is a 64 year-old CDL
license holder in North Carolina. He has
a history of seizures and has been
seizure free since 2008. He takes antiseizure medication with the dosage and
frequency remaining the same since
2008. His physician states that she is
supportive of Mr. Morrison receiving an
exemption.
Darrel Rinder
Mr. Rinder is a 56 year-old CDL
license holder in California. He has a
history of epilepsy and has been seizure
free since 1982. He takes anti-seizure
medication with the dosage and
frequency remaining the same since
1992. His physician states that he is
supportive of Mr. Rinder receiving an
exemption.
IV. Request for Comments
In accordance with 49 U.S.C. 31136(e)
and 31315(b), FMCSA requests public
comment from all interested persons on
the exemption petitions described in
this notice. We will consider all
comments received before the close of
business on the closing date indicated
under the DATES section of the notice.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020–20395 Filed 9–15–20; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2019–0069]
Parts and Accessories Necessary for
Safe Operation; Application for an
Exemption From Charles Machine
Works, Inc.
Federal Motor Carrier Safety
Administration (FMCSA),
Transportation (DOT).
ACTION: Notice of final disposition.
jbell on DSKJLSW7X2PROD with NOTICES
AGENCY:
The Federal Motor Carrier
Safety Administration (FMCSA)
announces its decision to grant Charles
Machine Works, Inc.’s (CMW)
SUMMARY:
VerDate Sep<11>2014
18:20 Sep 15, 2020
Jkt 250001
application for a limited 5-year
exemption to allow the use of gravity or
syphon-fed fuel systems for auxiliary
equipment installed on or used in
connection with commercial motor
vehicles (CMV). While the Federal
Motor Carrier Safety Regulations
(FMCSR) currently prohibit the use of
fuel systems that supply fuel directly to
the carburetor or injector by gravity or
syphon feed, the Agency has
determined that granting the exemption
to allow the use of gravity or syphon-fed
fuel systems for auxiliary equipment
that operates only when the CMV is
stationary would likely maintain a level
of safety that is equivalent to, or greater
than the level of safety provided by the
regulation.
DATES: This exemption is effective
September 16, 2020 and ending
September 16, 2025.
FOR FURTHER INFORMATION CONTACT: Mr.
Luke Loy, Vehicle and Roadside
Operations Division, Office of Carrier,
Driver, and Vehicle Safety, MC–PSV,
(202) 366–0676, Federal Motor Carrier
Safety Administration, 1200 New Jersey
Avenue SE, Washington, DC 20590–
0001.
Docket: For access to the docket to
read background documents or
comments submitted to notice
requesting public comments on the
exemption application, go to
www.regulations.gov at any time or visit
Room W12–140 on the ground level of
the West Building, 1200 New Jersey
Avenue SE, Washington, DC, between 9
a.m. and 5 p.m., ET, Monday through
Friday, except Federal holidays. To be
sure someone is there to help you,
please call (202) 366–9317 or (202) 366–
9826 before visiting Docket Operations.
The on-line Federal document
management system is available 24
hours each day, 365 days each year. The
docket number is listed at the beginning
of this notice.
SUPPLEMENTARY INFORMATION:
Background
FMCSA has authority under 49 U.S.C.
31136(e) and 31315 to grant exemptions
from certain parts of the FMCSRs.
FMCSA must publish a notice of each
exemption request in the Federal
Register (49 CFR 381.315(a)). The
Agency must provide the public an
opportunity to inspect the information
relevant to the application, including
any safety analyses that have been
conducted. The Agency must also
provide an opportunity for public
comment on the request.
The Agency reviews safety analyses
and public comments submitted, and
determines whether granting the
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
exemption would likely achieve a level
of safety equivalent to, or greater than,
the level that would be achieved by the
current regulation (49 CFR 381.305).
The decision of the Agency must be
published in the Federal Register (49
CFR 381.315(b)) with the reasons for
denying or granting the application and,
if granted, the name of the person or
class of persons receiving the
exemption, and the regulatory provision
from which the exemption is granted.
The notice must also specify the
effective period and explain the terms
and conditions of the exemption. The
exemption may be renewed (49 CFR
381.300(b)).
CMW’s Application for Exemption
CMW applied for an exemption from
49 CFR 393.65(d) to allow the use of
gravity or syphon-fed fuel systems for
auxiliary equipment installed on or
used in connection with CMVs that
operate only when the CMV is not
operating on the highway. A copy of the
application is included in the docket
referenced at the beginning of this
notice.
Section 393.65 of the FMCSRs
prescribes certain requirements that are
applicable to all CMV fuel systems. The
requirements in this section apply to
systems for containing and supplying
fuel for the operation of (1) motor
vehicles or (2) auxiliary equipment
installed on, or used in connection with,
motor vehicles. Section 393.65(d)
prohibits a fuel system from supplying
fuel by gravity or syphon feed directly
to the carburetor or injector.
CMW is a family of companies
focused on the installation,
maintenance, rehabilitation, and
replacement of underground pipe and
cable for the telecom, oil, electricity,
gas, water, and wastewater industries.
Its family of companies includes Ditch
Witch®, Subsite® Electronics, DW/
TXS®, HammerHead®, Trencor® and
MTI® Equipment. CMW designs,
manufactures and sells a range of
products to cover the full life-cycle of
underground pipe and cable, including
horizontal directional drills, walk and
ride trenchers, utility loaders, vacuum
excavators, asset locators, pipe
rehabilitation solutions, and aftermarket tools.
Some of the equipment designed and
manufactured by CMW utilizes small,
commercially available internal
combustion engines to power auxiliary
equipment that is permanently mounted
on a CMV. CMW states that while
auxiliary equipment that is permanently
mounted to CMVs is considered part of
the CMV and subject to the
requirements of 49 CFR 393.65(d), it
E:\FR\FM\16SEN1.SGM
16SEN1
Agencies
[Federal Register Volume 85, Number 180 (Wednesday, September 16, 2020)]
[Notices]
[Pages 57926-57928]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-20395]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2020-0050]
Qualification of Drivers; Exemption Applications; Epilepsy and
Seizure Disorders
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of applications for exemption; request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces receipt of applications from six individuals
for an exemption from the prohibition in the Federal Motor Carrier
Safety Regulations (FMCSRs) against persons with a clinical diagnosis
of epilepsy or any other condition that is likely to cause a loss of
consciousness or any loss of ability to control a commercial motor
vehicle (CMV) to drive in interstate commerce. If granted, the
exemptions would enable these individuals who have had one or more
seizures and are taking anti-seizure medication to operate CMVs in
interstate commerce.
DATES: Comments must be received on or before October 16, 2020.
ADDRESSES: You may submit comments identified by the Federal Docket
Management System (FDMS) Docket No. FMCSA-2020-0050 using any of the
following methods:
Federal eRulemaking Portal: Go to https://www.regulations.gov/docket?D=FMCSA-2020-0050. Follow the online
instructions for submitting comments.
Mail: Docket Operations; U.S. Department of
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
Hand Delivery: Docket Operations, West Building Ground
Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC, between
9 a.m. and 5 p.m., ET, Monday through Friday, except Federal Holidays.
To be sure someone is there to help you, please call (202) 366-9317 or
(202) 366-9826 before visiting Docket Operations.
Fax: (202) 493-2251.
To avoid duplication, please use only one of these four methods.
See the ``Public Participation'' portion of the SUPPLEMENTARY
INFORMATION section for instructions on submitting comments.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, (202) 366-4001, [email protected], FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal holidays. If you have questions
regarding viewing or submitting material to the docket, contact Docket
Operations, (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Public Participation
A. Submitting Comments
If you submit a comment, please include the docket number for this
notice (Docket No. FMCSA-2020-0050), indicate the specific section of
this document to which each comment applies, and provide a reason for
each suggestion or recommendation. You may submit your comments and
material online or by fax, mail, or hand delivery, but please use only
one of these means. FMCSA recommends that you include your name and a
mailing address, an email address, or a phone number in the body of
your document so that FMCSA can contact you if there are questions
regarding your submission.
To submit your comment online, go to https://www.regulations.gov/docket?D=FMCSA-2020-0050. Click on the ``Comment Now!'' button and type
your comment into the text box on the following screen. Choose whether
you
[[Page 57927]]
are submitting your comment as an individual or on behalf of a third
party and then submit.
If you submit your comments by mail or hand delivery, submit them
in an unbound format, no larger than 8\1/2\ by 11 inches, suitable for
copying and electronic filing. If you submit comments by mail and would
like to know that they reached the facility, please enclose a stamped,
self-addressed postcard or envelope.
FMCSA will consider all comments and material received during the
comment period.
B. Viewing Documents and Comments
To view comments, as well as any documents mentioned in this notice
as being available in the docket, go to https://www.regulations.gov/docket?D=FMCSA-2020-0050 and choose the document to review. If you do
not have access to the internet, you may view the docket online by
visiting Docket Operations in Room W12-140 on the ground floor of the
DOT West Building, 1200 New Jersey Avenue SE, Washington, DC 20590,
between 9 a.m. and 5 p.m., ET, Monday through Friday, except Federal
holidays. To be sure someone is there to help you, please call (202)
366-9317 or (202) 366-9826 before visiting Docket Operations.
C. Privacy Act
In accordance with 5 U.S.C. 553(c), DOT solicits comments from the
public to better inform its rulemaking process. DOT posts these
comments, without edit, including any personal information the
commenter provides, to www.regulations.gov, as described in the system
of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.transportation.gov/privacy.
II. Background
Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption
from the FMCSRs for no longer than a 5-year period if it finds such
exemption would likely achieve a level of safety that is equivalent to,
or greater than, the level that would be achieved absent such
exemption. The statute also allows the Agency to renew exemptions at
the end of the 5-year period. FMCSA grants medical exemptions from the
FMCSRs for a 2-year period to align with the maximum duration of a
driver's medical certification.
The six individuals listed in this notice have requested an
exemption from the epilepsy and seizure disorders prohibition in 49 CFR
391.41(b)(8). Accordingly, the Agency will evaluate the qualifications
of each applicant to determine whether granting the exemption will
achieve the required level of safety mandated by statute.
The physical qualification standard for drivers regarding epilepsy
found in Sec. 391.41(b)(8) states that a person is physically
qualified to drive a CMV if that person has no established medical
history or clinical diagnosis of epilepsy or any other condition which
is likely to cause the loss of consciousness or any loss of ability to
control a CMV.
In addition to the regulations, FMCSA has published advisory
criteria \1\ to assist medical examiners (MEs) in determining whether
drivers with certain medical conditions are qualified to operate a CMV
in interstate commerce.
---------------------------------------------------------------------------
\1\ These criteria may be found in Appendix A to Part 391--
Medical Advisory Criteria, section H. Epilepsy: Sec. 391.41(b)(8),
paragraphs 3, 4, and 5, which is available on the internet at
https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------
The criteria states that if an individual has had a sudden episode
of a non-epileptic seizure or loss of consciousness of unknown cause
that did not require anti-seizure medication, the decision whether that
person's condition is likely to cause the loss of consciousness or loss
of ability to control a CMV should be made on an individual basis by
the ME in consultation with the treating physician. Before
certification is considered, it is suggested that a 6-month waiting
period elapse from the time of the episode. Following the waiting
period, it is suggested that the individual have a complete
neurological examination. If the results of the examination are
negative and anti-seizure medication is not required, then the driver
may be qualified.
In those individual cases where a driver has had a seizure or an
episode of loss of consciousness that resulted from a known medical
condition (e.g., drug reaction, high temperature, acute infectious
disease, dehydration, or acute metabolic disturbance), certification
should be deferred until the driver has recovered fully from that
condition, has no existing residual complications, and is not taking
anti-seizure medication.
Drivers who have a history of epilepsy/seizures, off anti-seizure
medication and seizure-free for 10 years, may be qualified to operate a
CMV in interstate commerce. Interstate drivers with a history of a
single unprovoked seizure may be qualified to drive a CMV in interstate
commerce if seizure-free and off anti-seizure medication for a 5-year
period or more.
As a result of MEs misinterpreting advisory criteria as regulation,
numerous drivers have been prohibited from operating a CMV in
interstate commerce based on the fact that they have had one or more
seizures and are taking anti-seizure medication, rather than an
individual analysis of their circumstances by a qualified ME based on
the physical qualification standards and medical best practices.
On January 15, 2013, FMCSA announced in a Notice of Final
Disposition titled, ``Qualification of Drivers; Exemption Applications;
Epilepsy and Seizure Disorders,'' (78 FR 3069), its decision to grant
requests from 22 individuals for exemptions from the regulatory
requirement that interstate CMV drivers have ``no established medical
history or clinical diagnosis of epilepsy or any other condition which
is likely to cause loss of consciousness or any loss of ability to
control a CMV.'' Since that time, the Agency has published additional
notices granting requests from individuals for exemptions from the
regulatory requirement regarding epilepsy found in Sec. 391.41(b)(8).
To be considered for an exemption from the epilepsy and seizure
disorders prohibition in Sec. 391.41(b)(8), applicants must meet the
criteria in the 2007 recommendations of the Agency's Medical Expert
Panel (78 FR 3069).
III. Qualifications of Applicants
Robert S. Kessler
Mr. Kessler is a 31year-old Class C license holder in Kansas. He
has a history of epilepsy and has been seizure free since 2004. He
takes anti-seizure medication with the dosage and frequency remaining
the same since 2016. His physician states that he is supportive of Mr.
Kessler receiving an exemption.
Thomas J. Kline
Mr. Kline is a 56 year-old class C license holder in Pennsylvania.
He has a history of seizures and has been seizure free since 1990. He
takes anti-seizure medication with the dosage and frequency remaining
the same since 1990. His physician states that he is supportive of Mr.
Kline receiving an exemption.
Jeffrey T. Lang
Mr. Lang is a 60 year-old CDL license holder in Pennsylvania. He
has a history of a single witness seizure and has been seizure free
since 1996. He takes anti-seizure medication with the dosage and
frequency remaining the same since 1997. His physician states that he
is supportive of Mr. Lang receiving an exemption.
[[Page 57928]]
Ty Martin
Mr. Martin is a 45 year-old CDL license holder in West Virginia. He
has a history of seizures and has been seizure free since 2006. He
takes anti-seizure medication with the dosage and frequency remaining
the same since 2012. His physician states that she is supportive of Mr.
Martin receiving an exemption.
Rick S. Morrison
Mr. Morrison is a 64 year-old CDL license holder in North Carolina.
He has a history of seizures and has been seizure free since 2008. He
takes anti-seizure medication with the dosage and frequency remaining
the same since 2008. His physician states that she is supportive of Mr.
Morrison receiving an exemption.
Darrel Rinder
Mr. Rinder is a 56 year-old CDL license holder in California. He
has a history of epilepsy and has been seizure free since 1982. He
takes anti-seizure medication with the dosage and frequency remaining
the same since 1992. His physician states that he is supportive of Mr.
Rinder receiving an exemption.
IV. Request for Comments
In accordance with 49 U.S.C. 31136(e) and 31315(b), FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated under the DATES
section of the notice.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2020-20395 Filed 9-15-20; 8:45 am]
BILLING CODE 4910-EX-P